drugset / Trial / NCT06908876
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
Phase 2
Active not recruiting
150 enrolled
Innovent Biologics Technology Limited (Shanghai R&D Center)
RandomizedParallel-groupSingle-blindTreatment
Summary
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
Timeline
- Start
- 2025-04-24
- Primary completion
- 2026-12-31
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Faricimab | Monoclonal antibody | 6 mg | Intravitreal |
| Subject | IBI302 | Unknown | 4 mg | Intravitreal |
| Subject | IBI302 | Unknown | 8 mg | Intravitreal |